| ||
| Roche Skin Cancer Drug Impresses Zacks.com Data from the phase III trial (EURTAC) on Tarceva showed that compared with placebo, the first-line use of Tarceva almost doubled survival rates in patients with a genetically distinct type of advanced non-small cell lung cancer (NSCLC) and even ... See all stories on this topic » | ||
| ||
| Celgene Study of Abraxane Drug Discovery & Development Celgene announced the final results from a phase III study of Abraxane (paclitaxel albumin-bound particles for injectable suspension) in combination with carboplatin in patients with advanced non-small cell lung cancer (NSCLC). ... See all stories on this topic » | ||
| Merck Serono: Patient Enrollment Completed for Cilengitide's Pivotal Phase III ... Business Wire (press release) CERTO: Cilengitide and cetuximab (Erbitux ® ) in combination with platinum-based chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) d. ADVANTAGE: Cilengitide in combination of different regimens of ... See all stories on this topic » | ||
| Latest Generation Da Vinci Si Robot Continues to Redefine Standards of Care at ... Your-Story.org (press release) Robotic Brachytherapy and Sublobar Resection for T1 Non-Small Cell Lung Cancer in High Risk Patients. Ann Thorac Surg. 2010 Feb; 89(2):360-7.) The latest generation Da Vinci Si technology opens up a whole new category of what's labeled as "minimally ... See all stories on this topic » |
| ||
| Research uncovers genetic link between emphysema, lung cancer Although the new study showed PLAGL2 as a contributing factor in emphysema and lung cancer development, the diseases form in opposite ways. Emphysema arises from cell death or injury, while lung cancer involves uncontrolled cell growth. ... Labspaces.net Latest News RSS News Feed | ||
| Roche Skin Cancer Drug Impresses By Zacks Investment Research Data from the phase III trial (EURTAC) on Tarceva showed that compared with placebo, the first-line use of Tarceva almost doubled survival rates in patients with a genetically distinct type of advanced non-small cell lung cancer (NSCLC) ... DailyMarkets.com | ||
| Lecture Announcment: Cancer Genomics & series wrap-up By Kristi One of his main areas of research is to use genomics to predict outcomes in non-small cell lung cancer. He has authored and coauthored more than 100 publications in peer reviewed prestigious journals. He is the editor of the ASCO ... Bioinformatics@Becker | ||
| Tarceva Nearly Doubled the Time People with a Genetically Distinct ... By Kelly Dunst ... the first Phase III study with Tarceva® (erlotinib) in Western patients with a genetically distinct type of advanced non-small cell lung cancer (NSCLC). EURTAC showed that first-line Tarceva nearly doubled the time people with NSCLC ... Vadvert - UK Paid Press Release... | ||
| Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment ... By admin Recent experiences in non-small cell lung cancer patients have shown that a maintenance treatment given immediately after first-line treatment regimens can improve PFS and survival. Considering the toxicity profile of NGR-hTNF ... Mesothelioma Clinical Trials |
| ||
| Ganetespib Proven Effective for Non-Small Cell Lung Cancer ... Synta Pharmaceuticals has announced successful clinical responses from the Phase II trial of ganetespib in patients with advanced non-small cell lung cancer ... www.pharmaceutical-technology.com/news/news121041.html | ||
| Synta Announces Ganetespib Phase 2 Non-small Cell Lung Cancer ... LEXINGTON, Mass.--(BUSINESS WIRE)-- Synta Pharmaceuticals Corp. (NASDAQ:SNTA - News) today presented results. biz.yahoo.com/bw/110604/20110604005016.html?.v=1... | ||
| my mum has small cell lung cancer, is... - Cancer Chat - Cancer ... Re: my mum has small cell lung cancer, is anyone else going through the same? Hi Leigh,. Sorry, yesterday was a very surreal day. ... cancerchat.cancerresearchuk.org/message/35257 | ||
| Diagnostic value of pro-gastrin-releasing peptide for small cell ... Conclusions: ProGRP has better sensitivity and high specificity as an auxiliary indicator for the diagnosis of small cell lung cancer. affective.com/.../diagnostic-value-of-progastrinreleasing-pepti... |
This once a day Google Alert is brought to you by Google.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment